New antitoagulants;Les nouveaux anticoagulants

Annales Pharmaceutiques Francaises

Volumn 65, Issue 2, 2007, Pages 85-94

  Samama, M M ^a   Gerotziafas, G ^b  

^a HÔTEL DIEU   (France)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anti Xa; Anticoagulants; Antithrombin; Apixaban; Dabigatran; Rivaroxaban

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; ANTIDOTE; ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DANAPAROID; DERMATAN SULFATE; DESULFATOHIRUDIN; DROTRECOGIN; DROTRECOGINE; DU 176B; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; KALLIKREIN; LEPIRUDIN; LEPIRUDINE; MELAGATRAN; NAPSAGATRAN; OTAMIXABAN; PENTASACCHARIDE; RAZAXABAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TGN 255; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIMELAGATRAN;

BLEEDING; BLOOD CLOTTING; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG COST; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERANCE; HEART ATRIUM FIBRILLATION; KIDNEY; LIFE EXPECTANCY; LIVER METABOLISM; LUNG EMBOLISM; ORTHOPEDIC SURGERY; VENOUS THROMBOEMBOLISM;

EID: 33947373893     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4509(07)90021-8     Document Type: Conference Paper

References (49)

1. Samama MM. Les nouveaux antithrombotiques. La Presse Médicale 2005 ; 34 : 1309-14.
2. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 265S-86S.
3. Samama MM, Gerotziafas G. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (Fondaparinux). Thromb Res 2003; 109: 1-11.
4. Perzborn E, Strassburger J, Wilmen A, Pohlman J, Roehrig S, Schlemmer KH, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
5. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28: 351-70.
6. Eriksson BI, Dahl OE, Büller HR, Haas SK, Huisman MV, Kakkar AK, et al. A New oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaprin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO in randomized trial. J Thromb Haemost 2005; 3: 103-11.
7. Turpie AGG, Fischer WD, Bauer K, Kwong L, Gent M, Misselwitz F for the ODIXa-KNEE investigators. An oral, direct factor Xa inhibitor -BAY 59-7939 - for prophylaxis against venous thromboembolism after total knee replacement: a dose-ranging study. J Thromb Haemost 2005; 3: 2479-86.
8. Eriksson BI, Borris LC, Dahl OE, Haas SK, Huisman MV, Kakkar AK, et al. for the ODIXa-HIP Study investigators. Prevention of venous thromboembolism with an oral, direct factor Xa inhibitor - BAY 59-7939 - in elective hip replacement: a dose-ranging study. ISTH 2005, abstract 02544.
9. Linkins LA, Weitz JI. New anticoagulant therapy. Ann Rev Med 2005; 56: 63-77.
10. Jilma B, Marsik C, Mayr F, Graninger MT, Taylor FB Jr, Ribel MC, et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002; 72: 403-10.
11. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C. Efficacy and safety of tifacxogin (recombinant tissue factor pathway inhibitor) in severe sepsis : a randomized controlled trial. JAMA 2003; 290: 238-47.
12. Abraham E, Laterre PF, Garg R, et al. Drocogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-41.
13. Lee A, Agnelli G, Büller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative VTE in patients undergoing total knee replacement. Circulation 2001; 104: 74-8.
14. Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. The potential of aptamers as anticoagulants. Trends Cardiovasc Md 2005; 15: 41-5.
15. Feuerstein GZ, Toomey JR, Valocik R, Koster P, patel A, Blackburn MN. An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb Haemost 1999; 82: 1443-5.
16. Gerotziafas G, Samama MM. Heterogeneity of synthetic factor Xa inhibitors. Current Pharmaceutical Design 2005; 11: 3855-76.
17. Walenga JM, Jske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1-36.
18. Samama MM. Prevention de la maladie thromboembolique veineuse après chirurgie orthopérique majeure : état des lieux et place d'un inhibiteur synthétique et spécifique du facteur Xa. Rev Chir Orthop Réparatrice Appar Mot 2003 ; 89 : 712-24.
19. Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or Enoxaprin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004; 140: 867-73.
20. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous Fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
21. Ma O, Fareed J. Idraparinux sodium Sanofi-Aventis. Drugs 2004; 11: 1028-34.
22. PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in DVT : a phase II evaluation. Blood 1998; 100: 301 (abstract).
23. Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-9.
24. Becker RC, Alexander J, Dyke CK, Harrington RA. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost 2004; 92: 1182-93.
25. Roehrig S, Straub A, Pohlmann J, Lampe T, Penerstorfer J, Schlemmer KH, et al. Discovery of the novel antithrombotic agent -chloro-N-({5S)-2-oxo- 3- 5 [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-yl}methyl)thiophene-2- carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor J Med Chem 2005; 48: 5900-8.
26. Morishima Y, Furugohri T, Honda Y, Matsumoto C, Isobe K, Fukuda T, et al. Antithrombotic properties Of DU-176b, a novel orally active factor Xa inhibitor: inhibition of both arterial and venous thrombosis, and combination effects with other antithrombotic agents. ISTH 2005; abstract.
27. Quan ML, Lam PY, Han Q, Pinto DJ, He My, Li R, et al. Discovery of 1-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4- [2'-dimethyllaminomethyl] imidazol-1-yl]Phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2005; 48: 1729-44.
28. Di Nisio M, Middeldorp S, Büller HR. Drug Therapy: direct thrombin inhibitors. N Engl J Med 2005; 353: 1028-40.
29. Samama MM, Gerotziafas GT, Elalamy I, Horellou MH, Conard J. Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb 2002; 32: 218-24.
30. Kher A, Samama MM. Surveillance du traitement par les inhibiteurs directs de la thrombine : temps de céphaline avec activateur ou temps d'écarine. An Biol Clin 2000 ; 58 : 575-9.
31. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention:REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.
32. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. A phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-21.
33. Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kalebo P, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement : METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002; 87: 231-7.
34. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, et al. EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-6.
35. Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003; 1: 2119-30.
36. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703-12.
37. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, et al. METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 288-96.
38. Fiessinger JN, Huisman MV, Davidson BBL, Bounameaux H, Francis CW, Eriksson H, et al. THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681-9.
39. Schulmann S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-21.
40. Huisman MV, THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitors ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized double-blind, International study (abstract). J Thromb Haemost 2003; supp. Abstract OC003.
41. Gerotziafas GT, Depasse F, Chakroun T, Samama MM, Elalamy I. Recombinant factor VIIa partially reverses the inhibitory effect of Fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004; 91: 531-7.
42. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment and prevention. The seventh ACCP Conference of antithrombotic and thrombolytic therapy. Chest 2004; 126 (Suppl. 3) : 311S-337S.
43. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Artgatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-43.
44. Martin NB, Masson P, Sepulchre C et al. Pharmacologic and biochemical profiles of new venous antithrombotic β-D-Xyloside derivatives : potential antiathero/thrombotic drugs. Sem Thromb Hemost 1996; 22: 247-54.
45. Kearon C, Comp P, Douketis J, Royds R, Yamaka K, Gent M. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005; 5: 962-8.
46. Combe S, Chander C, Allen G, Kennedy A. Pharmacokinetics and pharmacodynamics of TGN 255, a novel intravenous direct thrombin inhibitor in healthy volunteers. Comparison with unfractionated heparin. ISTH 2005; Sydney, Australia abstract p. 1116.
47. Myers D, Wrobleski S, Londy F, Fex B, Hawley A, Schaub R, et al. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb Haemost 2002; 87: 374-82.
48. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation trial. J Thromb Haemost 2005; 3: 1590-6.
49. Samama MM. Ximelagatran/Melagatran. L'avenir des nouveaux médicaments antithrombine oraux. J Mal Vasc 2004; 29: 61-2.